Evidence map›Paper›PMID 41552643›Full record

ArticleIn silico pharmacology2026

In-silico assessment of phytochemical derivatives generated using CHEESE webserver for advancement of druggable candidate in pancreatic cancer therapy.

Christopher Busayo Olowosoke, Felix Oluwasegun Ishabiyi, Amal Bouribab, Aqsa Munir, Blessing Awoyemi, Winifred Njideka Nsofo, Amorha Chizoba Christabel, Jonah Ojochogwu Joy, Samir Chtita, Victor Omoboyede and 1 more

Abstract read
In one paragraph

Article in In silico pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christopher Busayo OlowosokeSchool of Science, RMIT University, PO Box 71, Melbourne, Bundoora, 3083 Australia.
Felix Oluwasegun IshabiyiResearch Development Unit, Institute of Bioinformatics and Molecular Therapeutics, Osogbo, Osun State Nigeria.
Amal BouribabLaboratory of Analytical and Molecular Chemistry, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, Morocco.
Aqsa Munir *Multan, Pakistan.
Blessing Awoyemi *Department of Microbiology, School of Life Sciences (SLS), Federal University of Technology Akure, P.M.B 704, Akure, Ondo State Nigeria.
Winifred Njideka Nsofo *Research Development Unit, Institute of Bioinformatics and Molecular Therapeutics, Osogbo, Osun State Nigeria.
Amorha Chizoba Christabel *Research Development Unit, Institute of Bioinformatics and Molecular Therapeutics, Osogbo, Osun State Nigeria.
Jonah Ojochogwu Joy *Department of Microbiology, Faculty of Natural Sciences Kogi State University Anyigba, Anyigba, Kogi State Nigeria.
Samir ChtitaLaboratory of Analytical and Molecular Chemistry, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, Morocco.
Victor OmoboyedeResearch Development Unit, Institute of Bioinformatics and Molecular Therapeutics, Osogbo, Osun State Nigeria.
Prosper Obed ChukwuemekaDepartment of Biotechnology, School of Life Sciences (SLS), Federal University of Technology Akure, P.M.B 704, Akure, Ondo State Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research efforts for pancreatic cancer (PC) therapy has led to investigations of numerous therapeutic targets, yet there are still limited efficacy outcomes. In 2021, the annual PC cases of 508,533 resulted in mortality of 505,752 for both sexes according to GLOBOCAN. In order to address this burden, enhancer of zeste homolog 2 (EZH2); an epigenetic regulator implicated in various cancers, has been an attractive target, due to promising tumor-suppressive effects in both preclinical and clinical studies. This effect was observed from drugs that have strong affinity towards EZH2, but there is need to improve the structural moieties for better interaction towards this protein. In this study, we employed a structure-based drug discovery approach using CHEESE webserver for rapid ligand-based screening to identify and evaluate phytochemical derivatives for their potential to bind EZH2. Five phytochemicals, namely Moracin P, Naringenin 5-rhamnoside, Pinostrobin 5- glucoside, Phytocassane A, and Sakuranin with best performance against EZH2-PPARs from our previous study was used to generate top ten new derivatives each. The derivatives were subjected to molecular docking, pharmacokinetic, and toxicity predictions. The top-performing derivative interacting with EZH2 were further subjected to ADMET profiling with favorable pharmacokinetic, toxicity properties, and meeting key drug-likeness criteria. Molecular docking results revealed that several derivatives of Moracin P, Naringenin 5-rhamnoside, and Phytocassane A displayed higher predicted binding affinities (- 6.4 to - 8.2 Kcal/mol) compared to the parent template previously assessed for EZH2, engaging critical residues through hydrogen bonds and hydrophobic interactions. Molecular dynamic simulation (MDS) over 200 ns further confirmed the stability of selected protein-ligand complexes, with Moracin_P7 and Pinostrobin 5-glucoside_5 exhibiting high degrees flexibility within the first 100 ns, but remained stable for the last 100 ns, while contact analysis highlighted consistent interactions with the active site residues Gln653, Asp657, Asp664, Ser669, Asn673, Phe678, His711 and Tyr731. Conclusively, these findings provide evidence that CHEESE webserver is suitable to generate phytochemical derivatives that can be explored as feasible candidate in EZH2 inhibitory study and laying the groundwork for further in-vitro and in-vivo validation. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00536-w.

Indexed as

ADMETCHEESE webserverEZH2Molecular dockingMolecular dynamics simulationPhytochemicals

Identifiers

PMID41552643
PMCPMC12804539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.